CHO Pharma

CHO Pharma PEG

PEG Ratio (Price/Earnings-to-Growth) of CHO Pharma (6586.TWO) as of Nov 3, 2026.

PEG

-

Last updated:

PEG Ratio (Price/Earnings-to-Growth) of CHO Pharma is 2026 - . PEG Ratio (Price/Earnings-to-Growth) of CHO Pharma was 2025 -2.85 . It decreases by % lower compared to the previous year.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

CHO Pharma Stock analysis

What does CHO Pharma do? CHO Pharma, Inc. develops and commercializes innovative biopharmaceutical products using proprietary glycan engineering technologies. The company focuses on eight technology categories: homogeneous antibody drugs, monoclonal antibodies for cancers and immune-related diseases, carbohydrate-related vaccines and drugs, anti-influenza drugs, Saccharin tablets, sugar probes, sugar molecular synthesis and identification, and derivative patents of innovation development plans. These products are targeted at medical and pharmaceutical markets requiring advanced therapeutic solutions. The company's revenue streams come from the development and commercialization of these specialized biopharmaceutical products. Its primary customers are healthcare providers, hospitals, and pharmaceutical distributors seeking advanced treatments for cancer, immune disorders, and infectious diseases. The company's technology segments include antibody therapies, vaccine development, and antiviral drug applications, all leveraging its glycan engineering platform. CHO Pharma's business model centers on leveraging its patented glycan engineering technologies to create and sell high-value pharmaceutical products. The company's product portfolio spans multiple therapeutic areas, including oncology, immunology, and virology, with a focus on developing innovative treatments that address unmet medical needs. Its commercialization strategy involves direct sales to healthcare institutions and partnerships with pharmaceutical distributors for broader market reach. CHO Pharma is one of the most popular companies on Eulerpool.

Frequently Asked Questions about CHO Pharma stock

On Eulerpool you can find the complete historical development of PEG Ratio (Price/Earnings-to-Growth) CHO Pharma since 2006 – with annual values, charts, and detailed analysis.

The PEG ratio adjusts the P/E ratio by the expected earnings growth rate. A PEG below 1 may indicate an undervalued stock relative to its growth potential.

PEG = P/E Ratio / Expected Annual EPS Growth Rate

To evaluate PEG Ratio (Price/Earnings-to-Growth)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for PEG Ratio (Price/Earnings-to-Growth).

A 'good' varies by industry and company stage. On Eulerpool, you can compare PEG Ratio (Price/Earnings-to-Growth)'s CHO Pharma with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — CHO Pharma

All Key Metrics — CHO Pharma